Celcuity Inc. (CELC) has secured U.S. Patent No. 12,350,276, protecting the clinical dosing regimen of its lead drug candidate, gedatolisib, for ER+/HER2- breast cancer patients.
This patent extends Celcuity’s exclusivity in the U.S. through 2042.
The company plans to release topline data for the PIK3CA wild-type cohort of the VIKTORIA-1 clinical trial in Q3 2025, followed by data for the PIK3CA mutant cohort in Q4 2025.
“This dosing regimen patent reflects our commitment to enhancing our intellectual property portfolio,” said Brian Sullivan, CEO and Co-Founder of the company.
